<DOC>
	<DOC>NCT00583297</DOC>
	<brief_summary>The ABCD clinical study (ClinicalTrials.gov Identifier NCT00187291) was designed to determine if a T-Wave Alternans (TWA) test is equivalent to an Electrophysiology Study (EPS) in predicting life-threatening heart rhythms in patients with ischemic heart disease, left ventricular dysfunction, and non-sustained tachycardia. The purpose of the ABCD Genetic sub-study is to identify genetic markers that predict TWA status and arrhythmia risk in this same population.</brief_summary>
	<brief_title>Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia, Ventricular</mesh_term>
	<criteria>Subjects previously enrolled in the ABCD trial sponsored by St. Jude Medical (ClinicalTrials.gov Identifier NCT00187291) patients with ischemic heart disease left ventricular ejection fraction (LVEF) &lt; 40% nonsustained ventricular tachycardia Individuals who were not previously enrolled in the ABCD trial are not eligible for this genetic substudy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Arrhythmia</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>T wave Alternans (TWA)</keyword>
	<keyword>Implanted Cardioverter Defibrillator(ICD)</keyword>
	<keyword>Biological Markers</keyword>
	<keyword>Molecular Genetics</keyword>
</DOC>